JPMorgan Chase Financial Company LLC Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement Nos. 333-236659 and 333-236659-01 Dated September 19, 2022 3yr MRNA Contingent Income Auto-Callable Securities This document provides a summary of the terms of the securities. Investors must carefully review the accompanying preliminary pricing supplement referenced below, product supplement, prospectus supplement and prospectus and the “Risk Considerations” on the following page, prior to making an investment decision. SUMMARY TERMS Issuer: JPMorgan Chase Financial Company LLC (“JPMorgan Financial”) Guarantor: JPMorgan Chase & Co. Underlying stock: Common stock of Moderna, Inc. (Bloomberg ticker: MRNA UW Equity) Early redemption: If, on any determination date (other than the final determination date), the closing price of the underlying stock is greater than or equal to the initial stock price, the securities will be automatically redeemed for an early redemption payment on the first contingent payment date immediately following the related determination date. No further payments will be made on the securities once they have been redeemed. The securities will not be redeemed early on any contingent payment date if the closing price of the underlying stock is below the initial stock price on the related determination date. Early redemption payment: The early redemption payment will be an amount equal to (i) the stated principal amount plus (ii) the contingent quarterly payment with respect to the related determination date. Contingent quarterly payment:  If, on any determination date, the closing price of the underlying stock is greater than or equal to the downside threshold level, we will pay a contingent quarterly payment of at least $0.535 (at least 5.35% of the stated principal amount) per security on the related contingent payment date. The actual contingent quarterly payment will be provided in the pricing supplement.  If, on any determination date, the closing price of the underlying stock is less than the downside threshold level, no contingent quarterly payment will be made with respect to that determination date. It is possible that the closing price of the underlying stock will be below the downside threshold level on most or all of the determination dates so that you will receive few or no contingent quarterly payments. Determination dates†: December 23, 2022, March 23, 2023, June 23, 2023, September 25, 2023, December 26, 2023, March 25, 2024, June 24, 2024, September 23, 2024, December 23, 2024, March 24, 2025, June 23, 2025 and September 23, 2025 Contingent payment dates†: December 29, 2022, March 28, 2023, June 28, 2023, September 28, 2023, January 2, 2024, March 28, 2024, June 27, 2024, September 26, 2024, December 27, 2024, March 27, 2025, June 26, 2025 and the maturity date Payment at maturity:  If the final stock price is greater than or equal to the downside threshold level: (i) the stated principal amount plus (ii) the contingent quarterly payment with respect to the final determination date  If the final stock price is less than the downside threshold level: (i) the stated principal amount times (ii) the stock performance factor. This cash payment will be less than 50% of the stated principal amount of the securities and could be zero. Downside threshold level: 50% of the initial stock price Initial stock price: The closing price of the underlying stock on the pricing date Final stock price: The closing price of the underlying stock on the final determination date Stock adjustment factor: The stock adjustment factor is referenced in determining the closing price of the underlying stock and is set initially at 1.0 on the pricing date. The stock adjustment factor is subject to adjustment in the event of certain corporate events affecting the underlying stock. Stock performance factor: final stock price / initial stock price Stated principal amount: $10 per security Issue price: $10 per security Pricing date: Expected to be September 23, 2022 Original issue date (settlement date): 3 business days after the pricing date Maturity date†: September 26, 2025 CUSIP / ISIN: 48133H168 / US48133H1683 Preliminary pricing supplement: http://www.sec.gov/Archives/edgar/data/1665650/000182912622016947/jpm_424b2.htm †Subject to postponement The estimated value of the securities on the pricing date will be provided in the pricing supplement and will not be less than $9.20 per $10 stated principal amount security. For information about the estimated value of the securities, which likely will be lower than the price you paid for the securities, please see the hyperlink above. Any payment on the securities is subject to the credit risk of JPMorgan Financial as issuer of the securities, and the credit risk of JPMorgan Chase & Co., as guarantor of the securities. Hypothetical Payout at Maturity (if the securities have not previously been redeemed) Change in Underlying Stock Payment at Maturity (excluding any coupon payable at maturity) 50.00% $10.000 40.00% $10.000 30.00% $10.000 20.00% $10.000 10.00% $10.000 5.00% $10.000 0.00% $10.000 -10.00% $10.000 -20.00% $10.000 -30.00% $10.000 -40.00% $10.000 -50.00% $10.000 -50.01% $4.999 -60.00% $4.000 -80.00% $2.000 -100.00% $0.000

 

JPMorgan Chase Financial Company LLC 3yr MRNA Contingent Income Auto-Callable Securities SEC Legend: JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. have filed a registration statement (including a prospectus) with the SEC for any offerings to which these materials relate. Before you invest, you should read the prospectus in that registration statement and the other documents relating to this offering that JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. has filed with the SEC for more complete information about JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. and this offering. You may get these documents without cost by visiting EDGAR on the SEC web site at www.sec.gov. Alternatively, JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co., any agent or any dealer participating in the this offering will arrange to send you the prospectus and each prospectus supplement as well as any product supplement and preliminary pricing supplement if you so request by calling toll-free 1-866-535-9248. Underlying Stock For more information about the underlying stock, including historical performance information, see the accompanying preliminary pricing supplement. Risk Considerations The risks identified below are not exhaustive. Please see “Risk Factors” in the accompanying prospectus supplement, product supplement and preliminary pricing supplement for additional information. Risks Relating to the Securities Generally  The securities do not guarantee the return of any principal and your investment in the securities may result in a loss.  You will not receive any contingent quarterly payment for any quarterly period if the closing price of the underlying stock on the relevant determination date is less than the downside threshold level.  The contingent quarterly payment is based solely on the closing prices of the underlying stock on the specified determination dates.  The securities are subject to the credit risks of JPMorgan Financial and JPMorgan Chase & Co., and any actual or anticipated changes to our or JPMorgan Chase & Co.’s credit ratings or credit spreads may adversely affect the market value of the securities.  As a finance subsidiary, JPMorgan Financial has no independent operations and has limited assets.  Investors will not participate in any appreciation of the underlying stock.  Early redemption risk.  Secondary trading may be limited.  The final terms and estimated valuation of the securities will be provided in the pricing supplement.  The U.S. federal income tax consequences of an investment in the securities are uncertain. Risks Relating to Conflicts of Interest  Economic interests of the issuer, the guarantor, the calculation agent, the agent of the offering of the securities and other affiliates of the issuer may be different from those of investors.  Hedging and trading activities by the issuer and its affiliates could potentially affect the value of the securities. Risks Relating to the Estimated Value and Secondary Market Prices of the Securities  The estimated value of the securities will be lower than the original issue price (price to public) of the securities.  The estimated value of the securities does not represent future values of the securities and may differ from others’ estimates.  The estimated value of the securities is derived by reference to an internal funding rate.  The value of the securities as published by J.P. Morgan Securities LLC (and which may be reflected on customer account statements) may be higher than the then-current estimated value of the securities for a limited time period.  Secondary market prices of the securities will likely be lower than the original issue price of the securities.  Secondary market prices of the securities will be impacted by many economic and market factors. Risks Relating to the Underlying Stock  Investing in the securities is not equivalent to investing in the underlying stock.  No affiliation with Moderna, Inc.  We may engage in business with or involving Moderna, Inc. without regard to your interests.  Limited trading history.  Government legislative and regulatory actions, including sanctions, could adversely affect your investment in the securities.  The anti-dilution protection for the underlying stock is limited and may be discretionary. Tax Considerations You should review carefully the discussion in the accompanying preliminary pricing supplement under “Additional Information about the Securities — Tax considerations” concerning the U.S. federal income tax consequences of an investment in the securities, and you should consult your tax adviser.